publication . Article . 2010

Osteoquimionecrosis de los maxilares asociada a la administración de bifosfonatos por vía endovenosa: a propósito de seis casos

E. Masip Zurriaga; M. Herrero Fonollosa; L. Berini Aytés; C. Gay Escoda;
Open Access Spanish; Castilian
  • Published: 01 Dec 2010
  • Publisher: Ediciones Avances
  • Country: Spain
Abstract
espanolLa osteonecrosis de los maxilares en pacientes con cancer se asociaba, hasta ahora, con la radioterapia, aunque recientemente se han reportado numerosos casos de osteoquimionecrosis de los maxilares (OQNM) relacionada con la quimioterapia, y mas concretamente con el uso de los bifosfonatos (agentes inhibidores de la actividad osteoclastica), utilizados para el tratamiento de las metastasis oseas. Los bifosfonatos inhiben la actividad osteoclastica dando lugar a una disminucion de la reabsorcion y la remodelacion del hueso, comprometiendo su irrigacion. Si bien la disminucion del aporte vascular en el hueso podria presentarse en cualquier localizacion, par...
Persistent Identifiers
Subjects
free text keywords: Maxil·lars, Ossos de la cara, Efectes secundaris dels medicaments, Jaws, Facial bones, Drug side effects, Bifosfonatos, osteonecrosis maxilar, osteoquimionecrosis de los maxilares, Bisphosphonates, jaw osteonecrosis, the jaw osteoquimionecrosis, Otorhinolaryngology, General Dentistry, Gynecology, medicine.medical_specialty, medicine, Surgery, business.industry, business, Treatment options, In patient
Related Organizations
31 references, page 1 of 3

1. Rogers MJ. New insights into the molecular mechanisns of action of bisphosphonates. Curr Pharm Des 2003;9: 2643-58.

2. Marx RE, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factor, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:1567-75.

3. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007; 86:1013-21.

4. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: A possible association. MJA 2005;182:404-15.

5. Luckman SP, Hughes DE, Coxson FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisfosfonates inhibit the mevalonate pathway and prevent port-translational prenylation of GTPbinding proteins, including Ras. J Bone Miner Res 1998;13:1668-78.

6. Pastor D, Garatea J, Martino R, Etayo A, Sebastán C. Osteonecrosis maxilar y bifosfonatos. Presentación de tres casos. Med Oral Patol Oral Cir Bucal 2006; 11:76-9.

7. Miller PD. Optimizing the management of post menopausal osteoporosis with bisphosphonates: The emerging role of intermittent therapy. Clin Ther 2005;27:371-6.

8. Dannemann C, Gratz KW, Reiner MO, Zwahlen RA. Jaw osteonecrosis related related to bisphosphonate therapy. A severe secondary disorder. Bone 2007;40:828-34.

9. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23: 826-36.

10. Pecherstorfer M, Brenner K, Zojer N. Current management strategies for hypercalcemia. Treat Endocrinol 2003;2:273-92.

11. Orcel P, Rousiere M. Paget's disease and its therapeutic management. Presse Med 2005; 34:612-6.

12. Lipton A. Efficacy of intravenous bisphosphonates with bone metastases caused by metastatic breast cancer. Clin Breast Cancer 2007; 7 Suppl 1:514-20.

13. Ruggiero SL, Menhrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of Bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.

14. Jiménez I, Bagán JV. Los bifosfonatos, nueva causa de osteonecrosis maxilar por fármacos: Situación actual. Med Oral Patol Oral Cir Bucal 2005; 10:88-91.

15. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: A clinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35:588-93. [OpenAIRE]

31 references, page 1 of 3
Any information missing or wrong?Report an Issue